Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
Chan-Loi YongJoseph C GatheGabriele KnechtCatherine OrrellJosep MallolasDaniel PodzamczerBenoit TrottierWei ZhangJohn P SaboRichard ViniskoMurray DrulakAnne-Marie QuinsonPublished in: HIV clinical trials (2018)
These data suggest NVP-XR achieves lower but effective NVP exposure compared with NVP-IR.